Experience

Remedium Bio

• United States
• Biotechnology
• 1 - 100 Employee

• Vice President, Research & Development

  • Nov 2021 - Present

  • Responsible for pre-clinical development of Remedium’s gene therapy programs utilizing viral and non-viral gene delivery technologies • Supervision of sponsored external research collaborations with academic partners • Development of plans and budgets for feasibility and proof of concept work • Advancement of intellectual property portfolio across the pipeline • Responsible for pre-clinical development of Remedium’s gene therapy programs utilizing viral and non-viral gene delivery technologies • Supervision of sponsored external research collaborations with academic partners • Development of plans and budgets for feasibility and proof of concept work • Advancement of intellectual property portfolio across the pipeline



Takeda

• Biotechnology
• 1 - 100 Employee

• Associate Director, Global Gene Therapy Research

  • Aug 2019 - Nov 2021

  • Led pre-clinical development of 4 therapeutic gene therapy programs utilizing non-viral and AAV-based gene delivery approaches • Headed the Vectorology and Molecular Biology research team within Global Gene Therapy Research, which supports vector engineering for Takeda’s gene therapy programs, as well as the development of novel vector systems • Co-inventor on a patent for a novel AAV vector technology (patent WO2020252136A1) • Led pre-clinical development of 4 therapeutic gene therapy programs utilizing non-viral and AAV-based gene delivery approaches • Headed the Vectorology and Molecular Biology research team within Global Gene Therapy Research, which supports vector engineering for Takeda’s gene therapy programs, as well as the development of novel vector systems • Co-inventor on a patent for a novel AAV vector technology (patent WO2020252136A1)



Solid Biosciences

• United States
• Biotechnology Research
• 1 - 100 Employee

• Associate Director, Vector Biology

  • Sep 2018 - Aug 2019

  • Development of a suspension-based process for rHSV production • Optimization and improvement of HSV-based production of AAV vectors for treatment of DMD • Optimization of the AAV vector • Development of a suspension-based process for rHSV production • Optimization and improvement of HSV-based production of AAV vectors for treatment of DMD • Optimization of the AAV vector



Bioverativ

• United States

• Scientist II

  • Feb 2017 - Sep 2018

  • Development of non-viral gene delivery technologies • Development of lentiviral vector-based gene therapy treatments for hemophilia A • Development of non-viral gene delivery technologies • Development of lentiviral vector-based gene therapy treatments for hemophilia A



Biogen

• South Africa
• Wellness and Fitness Services
• 1 - 100 Employee

• Scientist I

  • Sep 2015 - Jan 2017

  • Development of lentiviral and adeno-associated virus (AAV) vectors for antibody delivery • Development of lentiviral vectors for regulated genome editing • Development of gene therapy treatments for hemophilia A • Development of lentiviral and adeno-associated virus (AAV) vectors for antibody delivery • Development of lentiviral vectors for regulated genome editing • Development of gene therapy treatments for hemophilia A



UTMB

• United States
• Hospitals and Health Care

• Research Scientist I

  • May 2014 - Sep 2015

  • Development of a replication deficient adenovirus-based vaccine platform for infectious diseases• Developed all methods and protocols for rapid generation of adenovirus-based vaccine candidates for pre-clinical in vivo studies• Investigation of the molecular mechanisms of pathogenesis of arenaviruses Junin and Lassa• Development of therapeutics against filoviruses Ebola and Marburg• Supervision and scientific guidance of graduate students and technical personnel• 1 first-author book chapter, 1 first-author and 2 co-author peer-reviewed papers Show less

• Graduate Research Assistant

  • Jun 2010 - Apr 2014

  • Developed reverse genetics systems for highly pathogenic hemorrhagic viruses Junin and Lassa• Identified genetic determinants and proposed a molecular mechanism of Junin virus attenuation• Discovered novel viral targets for the development of vaccines and therapeutics against arenaviruses• Trained and supervised 4 graduate students and 2 Ph.D.-level researchers on molecular genetics and molecular biology techniques• Served as a Study Director on 4 animal studies conducted in high-containment ABSL-4 facilities• Obtained results that provided the basis for two successful grant applications ($4.84M awarded)• 1 first-author and 7 co-author peer-reviewed papers Show less

• Visiting Scientist

  • Dec 2007 - May 2010

  • Generated a highly protective alphavirus-vectored vaccine candidate against Junin virus• Directed a vaccine efficacy study in an animal model of lethal JUNV infection in a high-containment ABSL-4 facility• 1 first-author and 1 co-author peer-reviewed papers



University of Kansas

• United States
• Motor Vehicle Manufacturing
• 1 - 100 Employee

• Visiting Scientist

  • Jan 2003 - Jun 2007

  • Developed infectious cDNA reverse genetics systems for West Nile and Yellow Fever flaviviruses • Generated chimeric West Nile viruses suitable for vaccine development • Identified genetic determinants of West Nile virus pathogenesis in a mouse model • Designed and conducted pathogenesis studies in mice in a high-containment ABSL-3 facility • Trained 2 post-doctoral scientists and supervised 3 undergraduate students on molecular biology techniques • 1 first-author and 4 co-author peer-reviewed papers Show less